An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (NCT07197866)
An Open-Label Extension, Multi-Centered, Phase 2 Trial to Describe the Safety and Efficacy of TEV-56286 (Emrusolmin) in Participants With Multiple System Atrophy
🩺 Plain-English Summary (8th-Grade Level)
The primary objective of the trial is to describe the long-term safety and tolerability of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the trial is to further describe the safety and tolerability of TEV-56286. The planned total duration of the trial is approximately 100 weeks.
Who can join: Review the eligibility criteria below.
Location: Teva Investigational Site 15554 — La Jolla, California
Age range: 30 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (32 Sites)
Showing the first 25 of 32 sites.
- Teva Investigational Site 15554 — La Jolla, California
- Teva Investigational Site 15544 — Boca Raton, Florida
- Teva Investigational Site 15555 — Tampa, Florida
- Teva Investigational Site 15549 — New York, New York
- Teva Investigational Site 15551 — New York, New York
- Teva Investigational Site 15548 — Pittsburgh, Pennsylvania
- Teva Investigational Site 15543 — Spokane, Washington
- Teva Investigational Site 35290 — Bordeaux,
- Teva Investigational Site 35291 — Paris,
- Teva Investigational Site 35292 — Toulouse,
- Teva Investigational Site 32818 — Dresden,
- Teva Investigational Site 32822 — Düsseldorf,
- Teva Investigational Site 32825 — Kassel,
- Teva Investigational Site 32824 — Marburg,
- Teva Investigational Site 32820 — München,
- Teva Investigational Site 32819 — Münster,
- Teva Investigational Site 80203 — Haifa,
- Teva Investigational Site 80204 — Tel Aviv,
- Teva Investigational Site 30299 — Bologna,
- Teva Investigational Site 30298 — Milan,
- Teva Investigational Site 30296 — Roma,
- Teva Investigational Site 30295 — Salerno,
- Teva Investigational Site 84137 — Niigata,
- Teva Investigational Site 84138 — Sagamihara,
- Teva Investigational Site 84141 — Sanda-shi,
📞 Contact the Study Coordinator
Phone: (888) 483-8279
Email: USMedInfo@tevapharm.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple System Atrophy
- Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy — Rochester, Minnesota
- A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy — Los Angeles, California
- A Study of Lu AF82422 in Participants With Multiple System Atrophy — Fountain Valley, California
- GDNF Gene Therapy for Multiple System Atrophy — Irvine, California
- A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) — Scottsdale, Arizona
- Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic — Nashville, Tennessee
Explore by condition: All Multiple System Atrophy clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.